Literature DB >> 20837664

Telomerase inhibition potentiates the effects of genotoxic agents in breast and colorectal cancer cells in a cell cycle-specific manner.

Raina A Tamakawa1, Helen B Fleisig, Judy M Y Wong.   

Abstract

Previous studies have shown that telomerase facilitates DNA-damage repair and cell survival following stress. It is not clear how telomerase promotes DNA repair, or whether short-term telomerase inhibition, combined with genotoxic stress, can be exploited for cancer therapy. Here, we show that transient inhibition of telomerase activity by the specific inhibitor, GRN163L, increases the cytotoxicity of some, but not all, DNA-damaging agents. Such synergistic inhibition of growth requires the use of DNA-damaging agents that are toxic in the S/G(2) phase of the cell cycle. Notably, inhibition of Ataxia Telangiectasia Mutated (ATM) kinase, together with telomerase inhibition, synergistically increases the cytotoxicity induced by the G(2)-specific topoisomerase II inhibitor etoposide. By varying the timing of telomerase inhibition, relative to the timing of DNA damage, it is apparent that the prosurvival functions of telomerase occur at early stages of DNA damage recognition and repair. Our results suggest that the protective role of telomerase in cell cycle-restricted DNA damage repair could be exploited for combined anticancer chemotherapy. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837664     DOI: 10.1158/0008-5472.CAN-10-2227

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Telomerase reverse transcriptase expression protects transformed human cells against DNA-damaging agents, and increases tolerance to chromosomal instability.

Authors:  H B Fleisig; K R Hukezalie; C A H Thompson; T T T Au-Yeung; A T Ludlow; C R Zhao; J M Y Wong
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

2.  Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity.

Authors:  Cheryl M Koh; Ekta Khattar; Shi Chi Leow; Chia Yi Liu; Julius Muller; Wei Xia Ang; Yinghui Li; Guido Franzoso; Shang Li; Ernesto Guccione; Vinay Tergaonkar
Journal:  J Clin Invest       Date:  2015-04-20       Impact factor: 14.808

3.  A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines.

Authors:  Yi Shi; Lin Sun; Ge Chen; Dongyan Zheng; Li Li; Wanguo Wei
Journal:  Target Oncol       Date:  2015-04-29       Impact factor: 4.493

4.  Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.

Authors:  Koshi Imami; Naoyuki Sugiyama; Haruna Imamura; Masaki Wakabayashi; Masaru Tomita; Masatoshi Taniguchi; Takayuki Ueno; Masakazu Toi; Yasushi Ishihama
Journal:  Mol Cell Proteomics       Date:  2012-09-10       Impact factor: 5.911

5.  Novel connections between DNA replication, telomere homeostasis, and the DNA damage response revealed by a genome-wide screen for TEL1/ATM interactions in Saccharomyces cerevisiae.

Authors:  Brian D Piening; Dongqing Huang; Amanda G Paulovich
Journal:  Genetics       Date:  2013-02-01       Impact factor: 4.562

6.  Telomerase activity in breast cancer patients: association with poor prognosis and more aggressive phenotype.

Authors:  Ana Kulić; Natalija Dedić Plavetić; Stjepan Gamulin; Jasminka Jakić-Razumović; Damir Vrbanec; Maja Sirotković-Skerlev
Journal:  Med Oncol       Date:  2016-01-30       Impact factor: 3.064

7.  In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.

Authors:  Kyle R Hukezalie; Naresh R Thumati; Hélène C F Côté; Judy M Y Wong
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

8.  MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer.

Authors:  Chung-Wah Wu; Yu-Juan Dong; Qiao-Yi Liang; Xin-Qi He; Simon S M Ng; Francis K L Chan; Joseph J Y Sung; Jun Yu
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

9.  Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome.

Authors:  Lingeng Lu; Chong Zhang; Gongjian Zhu; Melinda Irwin; Harvey Risch; Guido Menato; Marco Mitidieri; Dionyssios Katsaros; Herbert Yu
Journal:  Breast Cancer Res       Date:  2011-06-06       Impact factor: 6.466

Review 10.  Telomerase as a useful target in cancer fighting-the breast cancer case.

Authors:  Hanna Holysz; Natalia Lipinska; Anna Paszel-Jaworska; Blazej Rubis
Journal:  Tumour Biol       Date:  2013-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.